LIFECORE BIOMEDICAL, INC. Variable Lease, Cost
LIFECORE BIOMEDICAL, INC. (LFCR) reported Variable Lease, Cost of $0 for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. variable lease, cost for the quarter ending 2025-05-25 was $0.00.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for the quarter ending 2024-05-26 was $0.00.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for the quarter ending 2020-05-31 was $672.00K.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for the quarter ending 2020-02-23 was $725.00K.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for fiscal 2024 was $306.00K, a 49.00% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for fiscal 2023 was $600.00K, a 47.78% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. variable lease, cost for fiscal 2022 was $406.00K, a 2606.67% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 7 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-KT · filed 2026-03-16 | |||||
| 2025-05-25 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 10-KT · filed 2026-03-16 | ||||
| 2025-02-23 | $0.00 10-Q · filed 2025-04-03 | |||||
| 2024-05-26 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $306.00K 10-KT · filed 2026-03-16 | ||||
| 2024-02-25 | $306.00K 10-Q · filed 2025-04-03 | |||||
| 2023-05-28 | $600.00K 10-K · filed 2024-08-26 | |||||
| 2022-05-29 | $406.00K 10-K · filed 2024-03-20 | $134.00K 10-K · filed 2022-09-14 | ||||
| 2021-05-30 | $15.00K 10-K/A · filed 2023-03-16 | $792.00K 10-K · filed 2021-07-29 | ||||
| 2020-05-31 | $672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $1.40M derived: sum of 2 quarters · filed 2021-07-29 | $1.93M derived: sum of 3 quarters · filed 2021-07-29 | $1.95M 10-K · filed 2021-07-29 | ||
| 2020-02-23 | $725.00K 10-Q · filed 2020-04-03 | $1.26M derived: sum of 2 quarters · filed 2020-04-03 | $1.28M 10-Q · filed 2020-04-03 | |||
| 2019-11-24 | $532.00K 10-Q · filed 2020-01-02 | $697.00K 10-Q · filed 2020-01-02 | ||||
| 2019-08-25 | $165.00K 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |